An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
Clinical trial NCT01240421 · APPROVED_FOR_MARKETING
Trial details
- NCT number
- NCT01240421
- Sponsor
- Eisai Inc.
- Status
- APPROVED_FOR_MARKETING
- Study type
- EXPANDED_ACCESS
- Start date
- 2011-03-01
- Primary completion
- 2015-03-01
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.